Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$17.8M
Burn Rate (Qtr)
$7.0M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q1 '22
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
DMK
Company Profile
DMK Pharmaceuticals (NASDAQ: DMK) (previously Adamis Pharma). is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Recent Posts
See what the community is saying - click to see full post.